Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
It feels good to be back! My first ASCO with @adela_bio and post-baby . I’m absorbing all the amazing content and trying to connect with my peers and clinicians! #asco26#tissuefreemrd
Adela is advancing methylome analysis to deliver sensitive, blood-based ctDNA testing options for patients with cancer. By enabling earlier detection and more precise monitoring of cancer, we help clinicians and biopharma partners make more confident, informed decisions
#ASCO26
Happy Thursday, #MHNCS26! Day 1's highlights include the first Keynote from Sana Karam, MD, PhD, a Patient Perspective from Hector Basham, the K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session, and more!
View the schedule: https://t.co/hu6Y71Z56K
Sheetal Parmar, SVP of medical affairs, women’s health, has been recognized as one of the 2025 Top 50 Women Leaders in Healthcare Technology by The Healthcare Technology Report. 👏 The annual distinction highlights leaders who are shaping the future of healthcare through scientific advancement, operational excellence and meaningful patient impact.
Since joining Natera in 2013, Sheetal has been instrumental in strengthening the clinical foundation of our women’s health portfolio. A board-certified genetic counselor specializing in prenatal diagnosis and screening, she leads a multidisciplinary medical affairs organization and plays a critical role in guiding clinical strategy, enhancing the design and execution of the clinical trials and shaping Natera's approach to educating and serving patients and their providers. Her leadership reflects a deep commitment to advancing standards of care and expanding access to innovative genetic testing.
Please join us in congratulating Sheetal on this outstanding achievement!
https://t.co/IJL0mvHKpN
I’m back!!!! First conference post-baby with my new company #adela come visit me at the booth to hear about tissue-free ctDNA MRD testing for HNSCC HPV+\- cancer #mhncs26#hnscc#astro#oncology#mrd
Last day at @CGAIGC conference, #CGAIGC24 baby G has been behaving - kicking away and enjoying all the sessions- 33 weeks and he is already becoming a @CGAIGC fellow
So interesting - takeaways from CDH1 25 years of research- 90+% of pt have signet ring cells but only 10-40% go on to develop cancer. EUS is safe alt to total Gastrectomy 😱😱 @CGAIGC#cgaigc24